ZYNLONTA®1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023 LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing cohort​ with no DLT and with early signs of efficacy ADCT-601 (targeting AXL): Reached MTD and currently in dose optimization; Early signs of antitumor activity in both monotherapy and in combination Multiple data catalysts expected in 2024 and with a cash runway now expected into 4Q 2025 LAUSANNE, Switzerland, ...

Love Employee Overview ADCs - antigen-drug conjugants - are among the hottest developments in cancer treatments. In combination with other drugs, they hold the promise of replacing chemotherapy on a whole host of cancers, because, unlike chemo, which is systemic and comes with severe side effects, ADCs target specific tumors with minimal impacts on healthy tissue. Sometimes called "Smart chemo," and "Cancer guided missiles," ADC's work by delivering a combination of an antibody and a cancer-cell killer to a ...

ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Eugenia Litz - Vice President of Investor Relations and Corporate Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Naureen Quibria - Capital One Securities Brian Cheng - JPMorgan Operator Welcome to the ADC Therapeutics Third Quarter 20 ...

Exhibit 99.1 Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and nine months ended September 30, 2023. Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated Interim Balance Sheet 4 Condensed Consolidated Interim Statement of Changes in Equity 5 Condensed Consolidated Interim Statement of Cash Flows 7 Notes to the Condensed Consolidated Interim Financial Statements 8 ADC Thera ...

ADC Therapeutics SA (NYSE:ADCT) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Eugenia Litz - Vice President of Investor Relations and Corporate Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Kelly Shi - Jefferies Naureen Quibria - Capital One Securities Michael Riad - Morgan Stanley Brian Chan - JPMorgan Operator ...

2Q 2023 Earnings Call Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or ADC Therapeutics or any officer, director, employee, agent or advisor of ADC Therapeutics. This presentation does not purport to be ...

Exhibit 99.1 Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and six months ended June 30, 2023. Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated Interim Balance Sheet 4 Condensed Consolidated Interim Statement of Changes in Equity 5 Condensed Consolidated Interim Statement of Cash Flows 7 Notes to the Condensed Consolidated Interim Financial Statements 8 ADC Therapeutic ...

1Q 2023 Earnings Call Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter orADC Therapeutics or any officer, director, employee, agent or advisor of ADC Therapeutics. This presentation does not purport to be a ...

Exhibit 99.1 Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three months ended March 31, 2023. Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated Interim Balance Sheet 4 Condensed Consolidated Interim Statement of Changes in Equity 5 Condensed Consolidated Interim Statement of Cash Flows 6 Notes to the Condensed Consolidated Interim Financial Statements 7 ADC Therapeutics SA Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...